Suicidal ideation in a European Huntington's disease population

Hubers, Anna A.M.; Duijn, Erik van; Roos, Raymund A.C.; Craufurd, David; Rickards, Hugh; Landwehrmeyer, G. Bernhard; Mast, Rose C. van der; Giltay, Erik J.

doi:10.1016/j.jad.2013.06.001

Cited by 75 publications

(56 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some cases, it is accompanied by aggressiveness and anxiety as a consequence of a high burden of disease not only in patients but also in relatives and caregivers [41] . Therefore, support services for both patient and family are vital [42][43][44] .…”

Section: Discussionmentioning

confidence: 99%

Monitoring Huntington's Disease Mortality across a 30-Year Period: Geographic and Temporal Patterns

Sánchez-Díaz

Arias-Merino²,

Villaverde-Hueso³

et al. 2016

Neuroepidemiology

View full text Add to dashboard Cite

Background: Huntington's disease (HD) is a progressive neurodegenerative condition characterized by chorea, dystonia, behavioral disturbances and cognitive decline. The aim of this study is to assess temporal and spatial changes on mortality attributable to HD over 30 years in Spain. Methods: HD data were extracted from the nationwide mortality registry for the period 1984-2013. Annual and 5-year gender- and age-specific rates adjusted for the standard European population were calculated. Geographic analysis was performed by districts from 1999 through 2013, and then estimated standardized mortality ratios (SMRs) and smoothed SMRs. Results: There were 1,556 HD-related deaths across the study period. An increasing trend in age-adjusted HD mortality was in evidence, specifically from 1994 through 1998. On a year-by-year basis, age-adjusted mortality rates increased from 0.076 per 100,000 population in 1984 to 0.157 in 2013. Geographical differences among districts were evident in specific areas and in the southwest of Spain with a significantly higher HD mortality risk. Conclusion: HD mortality rising trends in Spain might be attributable to improvements in diagnosis leading to a rise in prevalence. Geographical variability in HD mortality could be related to regional differences in disease prevalence, health-care disparities, or other factors which call for in-depth assessment in future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Monitoring Huntington's Disease Mortality across a 30-Year Period: Geographic and Temporal Patterns

Sánchez-Díaz

Arias-Merino²,

Villaverde-Hueso³

et al. 2016

Neuroepidemiology

View full text Add to dashboard Cite

show abstract

“…Moreover, some studies have reported that the stage of illness in HD patients does not influence anxiety levels, contrary to depression symptoms [56]. As stated above, assuming benzodiazepine seems to be an independent risk factor for suicide (Table 4) [22,23,24,34,36,38,52]. …”

Section: Clinical Features In Hd and Psychiatric Disordersmentioning

confidence: 98%

“…However, recent studies have confirmed the need to distinguish suicide ideation from attempted suicide, as well as considering differently several groups with different characteristics in order not to introduce confounding data. In particular, depressive symptoms, anxiety, and benzodiazepine consumption are considered risk factors (Table 3) [32,35,52,53,54]. A history of suicide attempts and the presence of depression are strongly predictive of suicidal behavior in prodromal HD.…”

Section: Clinical Features In Hd and Psychiatric Disordersmentioning

confidence: 99%

Neuropsychiatric Burden in Huntington’s Disease

et al. 2017

View full text Add to dashboard Cite

Huntington’s disease is a disorder that results in motor, cognitive, and psychiatric problems. The symptoms often take different forms and the presence of disturbances of the psychic sphere reduces patients’ autonomy and quality of life, also impacting patients’ social life. It is estimated that a prevalence between 33% and 76% of the main psychiatric syndromes may arise in different phases of the disease, often in atypical form, even 20 years before the onset of chorea and dementia. We present a narrative review of the literature describing the main psychopathological patterns that may be found in Huntington’s disease, searching for a related article in the main database sources (Medline, ISI Web of Knowledge, Scopus, and Medscape). Psychiatric conditions were classified into two main categories: affective and nonaffective disorders/symptoms; and anxiety and neuropsychiatric features such as apathy and irritability. Though the literature is extensive, it is not always convergent, probably due to the high heterogeneity of methods used. We summarize main papers for pathology and sample size, in order to present a synoptic vision of the argument. Since the association between Huntington’s disease and psychiatric symptoms was demonstrated, we argue that the prevalent and more invalidating psychiatric components should be recognized as early as possible during the disease course in order to best address psychopharmacological therapy, improve quality of life, and also reduce burden on caregivers.

show abstract

“…Suicidality is more common among gene carriers than noncarriers, and needs to be addressed with these patients. 34 …”

Section: Huntington Diseasementioning

confidence: 99%

Genetic Testing and Counseling in the Diagnosis and Management of Young-Onset Dementias

Goldman

2015

Psychiatric Clinics of North America

View full text Add to dashboard Cite

Suicidal ideation in a European Huntington's disease population

Abstract: Suicidal ideation in HD frequently occurs. Assessment of suicidal ideation is a priority in mutation carriers with a depressed mood and in those using benzodiazepines.

Cited by 75 publications

References 30 publications

Monitoring Huntington's Disease Mortality across a 30-Year Period: Geographic and Temporal Patterns

Monitoring Huntington's Disease Mortality across a 30-Year Period: Geographic and Temporal Patterns

Neuropsychiatric Burden in Huntington’s Disease

Genetic Testing and Counseling in the Diagnosis and Management of Young-Onset Dementias

Contact Info

Product

Resources

About